What is 4P Pharma?
Established in 2014, 4P Pharma is a clinical-stage biotechnology firm dedicated to pioneering novel treatments for conditions with high unmet medical needs. The company operates as a strategic R&D partner, collaborating with academic institutions, private entities, and life science investors. Through a co-risk, co-share model, 4P Pharma aims to optimize risk management and expedite the drug development pipeline. Their patient-centric approach is augmented by partnerships with leading academic and AI technology organizations, facilitating the sourcing of promising therapeutic candidates. This robust R&D engine is designed for the swift market introduction of impactful therapies, supported by comprehensive preclinical development and strategic market access planning.
How much funding has 4P Pharma raised?
4P Pharma has raised a total of $16.1M across 1 funding round:
Other Financing Round
$16.1M
Other Financing Round (2024): $16.1M, investors not publicly disclosed
What's next for 4P Pharma?
The recent major strategic investment signals a pivotal phase for 4P Pharma, likely enabling the acceleration of its clinical development programs and the expansion of its therapeutic pipeline. This capital infusion is expected to bolster its R&D efforts, potentially leading to key milestones in drug candidate advancement and regulatory submissions. The company's focus on co-risk, co-share partnerships suggests a strategy geared towards efficient resource allocation and de-risking of late-stage development, positioning 4P Pharma for sustained growth and market impact in the competitive biotech landscape.
See full 4P Pharma company page
